[对19名新治疗的多发性骨髓瘤患者的预后分析, t(14; 16) ]

Y Li1, J R Liu2, J Li2

  • 1Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Myeloma Research Center of Beijing, Beijing 100020, China Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for Hematological Diseases, Beijing 100044, China.

概括

新诊断多发性骨髓瘤 (MM) 患者的t(14;16) 遗传异常表明预后不佳,类似于其他高风险遗传标记,如t(4;14) 和del(17p). 这一发现强调了t(14;16) 作为MM的显著不良预后因素.